Obermatt

TriSalus Life Sciences

NMQ:TLSI · US89680M1018
BiotechnologyX-Small

360

62
Profit price89
Owner Earnings Yield1
Dividend Yield1
Price/Sales96
EV / Gross Profit23
Price/Book93
Return on Capital17
Cash Return on Capital13
Return on Equity98
EBIT Margin28
Gross Profitability94
Accruals60
Owner Earnings Margin70
Sales growth66
Profit growth86
Reinvestment58
Price momentum4
Debt load9
Refinancing83
Debt Payback1
Liquidity84
Analyst ratings76
Opinion Changes50
Price Target Upside55
Market mood22
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

TriSalus Life Sciences clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQGM
Employees118
ISINUS89680M1018
Last UpdateApr 2, 2026
Themes
Health DiagnosticsImmunologyHepatologyArtificial IntelligenceOncologyBiotechnologyDeveloper PlatformHardwareMedical

Description

TriSalus Life Sciences, Inc. (TriSalus) operates as a commercial-stage medical device and Phase I clinical-stage pharmaceutical company. The company is a growing, oncology-focused medical technology business seeking to transform outcomes for patient…

Analysis

Middle-of-the-road

TriSalus Life Sciences, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
81
2026

All-time high

92

Mar 2026

All-time low

81

Jun 2026

Average rank

87

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
Price/Earnings
77
Price/Book
93
Dividend Yield
1
Value (overall)
91

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare TriSalus Life Sciences with its peers
Quince Therapeutics
NSQ:QNCX
4
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Regeneron Pharmaceuticals
NSQ:REGN
83
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Xencor
NMQ:XNCR
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →